Stockscreener 앱 받기
44.49
0.80%
-0.36
시간 외 거래:
44.49
Protagonist Therapeutics Inc 주식(PTGX)의 최신 뉴스
Daily Progress: Protagonist Therapeutics Inc (PTGX) Drop -2.84, Closing at 44.85 - DWinneX
Bank of Montreal Can Increases Stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - Defense World
Protagonist Therapeutics Announces Plenary Presentation on VERIF - GuruFocus
Protagonist Therapeutics CFO Sells Shares to Cover Tax Obligation - TradingView
Protagonist Therapeutics Announces Plenary Presentation on VERIFY Phase 3 Study with Rusfertide at ASCO 2025 | PTGX Stock News - GuruFocus
Press Release Distribution & PR Platform - ACCESS Newswire
Protagonist Therapeutics Announces Plenary Presentation on VERIFY Phase 3 Study with Rusfertide at ASCO 2025 - standard-journal.com
Major Clinical Breakthrough: Rusfertide Phase 3 PV Treatment Data Earns Coveted ASCO Plenary Spot - Stock Titan
Cerity Partners LLC Sells 1,185 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - Defense World
Legal & General Group Plc Lowers Stock Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - Defense World
When the Price of (PTGX) Talks, People Listen - news.stocktradersdaily.com
Protagonist Therapeutics Reports Granting of Inducement Award | PTGX Stock News - GuruFocus
Protagonist Awards 20,000 Stock Options to Key New Hire at $46.95 - Stock Titan
Alliancebernstein L.P. Trims Stock Holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - Defense World
The 4.2% return this week takes Protagonist Therapeutics' (NASDAQ:PTGX) shareholders five-year gains to 558% - simplywall.st
Geode Capital Management LLC Buys 2,366 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - Defense World
Protagonist Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:PTGX - Benzinga
Polycythemia Vera Market to Show Remarkable Growth Trends from - openPR.com
BTIG maintains Buy on Protagonist Therapeutics stock, $82 target By Investing.com - Investing.com Canada
Johnson & Johnson, Protagonist Tout Positive Results For Psoriasis Oral Pill Study - Benzinga
Protagonist Therapeutics (PTGX) Unveils Promising Data for Psori - GuruFocus
Revolutionary Once-Daily Pill Achieves Complete Skin Clearance in 75% of Teen Psoriasis Patients - Stock Titan
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Sold by Sei Investments Co. - Defense World
Winners and wishers: 9 potential Bay Area drug approvals coming this yearSan Francisco Business Times - The Business Journals
(PTGX) Investment Analysis - news.stocktradersdaily.com
Wall Street Analysts See a 27.36% Upside in Protagonist Therapeutics (PTGX): Can the Stock Really Move This High? - Yahoo Finance
Protagonist Therapeutics Named to Fast Company's Annual List of the World's Most Innovative Companies of 2025 - Bluefield Daily Telegraph
Why Protagonist Therapeutics, Inc. (PTGX) Went Up on Monday - MSN
Insider Sell: William Waddill Sells 4,000 Shares of Protagonist Therapeutics Inc (PTGX) - GuruFocus
Protagonist Therapeutics Takeda To Lead Regulatory Strategy For Rusfertide In Polycythemia Vera NDA - MarketScreener
INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Protagonist Therapeutics, Inc. With Losses of $100,000 to Contact the Firm - Business Wire
Protagonist Therapeutics (PTGX) Upgraded to Buy: Here's Why - MSN
Protagonist Therapeutics director Waddill sells $217,000 in stock By Investing.com - Investing.com South Africa
Protagonist Therapeutics director Waddill sells $217,000 in stock - Investing.com
Analysts Mentions Growth Catalysts for Protagonist Therapeutics (PTGX) — Best Biotech Stock for 2025? - MSN
These 10 biotech companies are changing how we discover new drugs and treat complex diseases - Fast Company
Fast Company Ranks Protagonist Among Elite Biotech Innovators: 2 FDA Filings Coming - StockTitan
D-Wave Quantum And IonQ Are Among Top Mid-Cap Stock Gainers Last Week (Mar 10-Mar 14): Are The Others In Your Portfolio? - Benzinga
Is Protagonist Therapeutics, Inc. (PTGX) the Best Healthcare Stock For Long-Term Investment? - Insider Monkey
Protagonist Therapeutics CFO Ali Asif sells $1.46 million in stock By Investing.com - Investing.com South Africa
Protagonist Therapeutics’ chief medical officer sells $1.7 million in stock By Investing.com - Investing.com Canada
Protagonist Therapeutics CFO Ali Asif sells $1.46 million in stock - Investing.com India
Protagonist Therapeutics’ chief medical officer sells $1.7 million in stock - Investing.com
Protagonist Therapeutics (NASDAQ:PTGX) Price Target Raised to $76.00 - Defense World
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Purchased by Victory Capital Management Inc. - Defense World
0.24%
36.06%
자본화:
|
볼륨(24시간):